Apixaban is a factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, among other approved uses. It is available as tablets, kits and capsules for oral use. MedsAcross supplies Apixaban for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ELIQUIS is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy.
Source: US FDA prescribing information
Apixaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.
Source: US FDA prescribing information
Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation: The recommended dose is 5 mg orally twice daily. In patients with at least 2 of the following characteristics: age greater than or equal to 80 years, body weight less than or equal to 60 kg, or serum creatinine greater than or equal to 1.5 mg/dL, the recommended dose is 2.5 mg orally twice daily. Prophylaxis of DVT following hip or knee replacement surgery: The recommended dose is 2.5 mg orally twice daily. Treatment of DVT and PE: The recommended dose is 10 mg taken orally twice daily for 7 days, followed by 5 mg taken orally twice daily. Reduction in the risk of recurrent DVT and PE following initial therapy: The recommended dose is 2.5 mg taken orally twice daily.
Source: US FDA prescribing information
ELIQUIS is contraindicated in patients with the following conditions: Active pathological bleeding Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions) Active pathological bleeding. Severe hypersensitivity to ELIQUIS
Source: US FDA prescribing information
Boxed warning: Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant. ELIQUIS can cause serious, potentially fatal, bleeding. Promptly evaluate signs and symptoms of blood loss. An agent to reverse the anti-factor Xa activity of apixaban is available. Prosthetic heart valves: ELIQUIS use not recommended. Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome: ELIQUIS use not recommended.
Source: US FDA prescribing information
The following clinically significant adverse reactions are discussed in greater detail in other sections of the prescribing information. Increased Risk of Thrombotic Events After Premature Discontinuation Bleeding Spinal/Epidural Anesthesia or Puncture Most common adverse reactions (>1%) are related to bleeding.
Source: US FDA prescribing information
Apixaban is a substrate of both CYP3A4 and P-gp. Inhibitors of CYP3A4 and P-gp increase exposure to apixaban and increase the risk of bleeding. Inducers of CYP3A4 and P-gp decrease exposure to apixaban and increase the risk of stroke and other thromboembolic events. Combined P-gp and strong CYP3A4 inhibitors increase blood levels of apixaban. Reduce ELIQUIS dose or avoid coadministration. Simultaneous use of combined P-gp and strong CYP3A4 inducers reduces blood levels of apixaban: Avoid concomitant use.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F-77°F), excursions permitted between 15°C and 30°C (59°F-86°F). Storage and Handling Store at 20°C to 25°C (68°F-77°F), excursions permitted between 15°C and 30°C (59°F-86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
7 presentations of Apixaban, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Eliquis 5 mg tabletOral | ER Squibb & Sons | US FDA | Available on request |
| Eliquis 2.5 mg tabletOral | ER Squibb & Sons | US FDA | Available on request |
| Apixaban 2.5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Apixaban 5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Eliquis 0.5 mg tablet for oral suspensionOral | ER Squibb & Sons | US FDA | Available on request |
| ELIQUIS 30-Day Starter Pack kit | ER Squibb & Sons | US FDA | Available on request |
| Eliquis Sprinkle 0.15 mg capsuleOral | ER Squibb & Sons | US FDA | Available on request |
3 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Apixaban in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 7 presentations of Apixaban and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 3 brand names for Apixaban, including Eliquis, ELIQUIS 30-Day Starter Pack, Eliquis Sprinkle.
Yes. The US FDA first approved Apixaban on 28 December 2012, according to Drugs@FDA.
Yes. Apixaban has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Apixaban is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Apixaban is classified under ATC code B01AF02 (Apixaban).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.